Results 41 to 50 of about 260,030 (390)
, 2022 Knjiga z naslovom »Geopark Kras« je poseben izdelek, saj priča o uspešnem čezmejnem sodelovanju, katerega skupni rezultat bo rojstvo čezmejnega geoparka na matičnem Krasu. Knjigo smo pripravili v projektu GeoKarst, ki je sofinanciran v okviru Programa sodelovanja Interreg V-A Italija - Slovenija 2014–2020.
Bensi S. +9 more
openaire
A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. [PDF]
, 2012 Endometriosis is found in 5-15% of women of reproductive age and is more frequent in relatives of women with the disease. Activation of KRAS results in de novo endometriosis in mice, however, activating KRAS mutations have not been identified in women ...
Chan, Elcie +8 more
core +1 more source
Targeting copper metabolism to defeat KRAS-driven colorectal cancer
Molecular & Cellular Oncology, 2020 KRAS-driven cancers acquire profound metabolic dependencies that are intimately linked to tumor growth. Our work revealed that colorectal cancers that harbor KRAS mutations are addicted to copper metabolism. This adaptation renders tumor cells critically
Léo Aubert +2 more
doaj +1 more source
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Cancer Discovery, 2022 KRAS is the most frequently mutated oncogene, harboring mutations in approximately one in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment paradigm for patients with KRASG12C-mutated non–small cell lung cancer and ...
M. H. Hofmann +4 more
semanticscholar +1 more source
KRAS-G12C in the crosshairs [PDF]
Nature Reviews Cancer, 2019 Two papers report the discovery and preclinical analyses of two different covalent inhibitors of KRAS-G12C (AMG 510 and MRTX849) as well as the first data on the efficacy of these inhibitors in cancer patients.
openaire +2 more sources
Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial. [PDF]
, 2019 BackgroundEconomic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated.MethodsTo illustrate ...
Chen, Bingshu E +12 more
core +1 more source
Roczniki Historyczne, 2014 „Wie sollen die Füchse im Weinberg des Herrn gefangen werden?” Antihäretische Inhalte in den Predigten Bernhards von Clairvaux und Helinands von Froidmont Zusammenfassung Seit der Mitte des 12.
Paweł Kras
doaj +1 more source
A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors
Molecular & Cellular Oncology, 2020 Previous analysis of Phase 3 clinical trial data for colorectal cancer patients treated with cetuximab revealed that patients harboring a KRAS mutation did not benefit from treatment.
Thomas McFall, Edward Cooper Stites
doaj +1 more source
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Molecular Cancer, 2022 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with drugs is challenging because KRAS is considered undruggable due to the lack of classic drug ...
Chunxi Zhu +7 more
semanticscholar +1 more source
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations [PDF]
Genes & Cancer, 2011 KRAS is a potent oncogene and is mutated in about 30% of all human cancers. However, the biological context of KRAS-dependent oncogenesis is poorly understood. Genetically engineered mouse models of cancer provide invaluable tools to study the oncogenic process, and insights from KRAS-driven models have significantly increased our understanding of the ...
Joerg Heyer, Rónán C. O’Hagan
openaire +3 more sources